全文获取类型
收费全文 | 1879篇 |
免费 | 119篇 |
国内免费 | 28篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 66篇 |
妇产科学 | 30篇 |
基础医学 | 231篇 |
口腔科学 | 55篇 |
临床医学 | 146篇 |
内科学 | 400篇 |
皮肤病学 | 40篇 |
神经病学 | 72篇 |
特种医学 | 158篇 |
外科学 | 260篇 |
综合类 | 37篇 |
预防医学 | 119篇 |
眼科学 | 82篇 |
药学 | 101篇 |
中国医学 | 4篇 |
肿瘤学 | 218篇 |
出版年
2024年 | 5篇 |
2023年 | 12篇 |
2022年 | 33篇 |
2021年 | 70篇 |
2020年 | 41篇 |
2019年 | 44篇 |
2018年 | 39篇 |
2017年 | 39篇 |
2016年 | 38篇 |
2015年 | 42篇 |
2014年 | 82篇 |
2013年 | 88篇 |
2012年 | 97篇 |
2011年 | 101篇 |
2010年 | 83篇 |
2009年 | 81篇 |
2008年 | 110篇 |
2007年 | 123篇 |
2006年 | 72篇 |
2005年 | 84篇 |
2004年 | 60篇 |
2003年 | 67篇 |
2002年 | 41篇 |
2001年 | 34篇 |
2000年 | 32篇 |
1999年 | 42篇 |
1998年 | 45篇 |
1997年 | 46篇 |
1996年 | 41篇 |
1995年 | 21篇 |
1994年 | 20篇 |
1993年 | 21篇 |
1992年 | 10篇 |
1991年 | 13篇 |
1990年 | 19篇 |
1989年 | 28篇 |
1988年 | 22篇 |
1987年 | 17篇 |
1986年 | 23篇 |
1985年 | 20篇 |
1984年 | 11篇 |
1983年 | 16篇 |
1982年 | 12篇 |
1981年 | 5篇 |
1980年 | 14篇 |
1978年 | 5篇 |
1977年 | 9篇 |
1976年 | 10篇 |
1975年 | 5篇 |
1969年 | 6篇 |
排序方式: 共有2026条查询结果,搜索用时 15 毫秒
81.
Post‐transplantation cyclophosphamide versus conventional graft‐versus‐host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation 下载免费PDF全文
Rohtesh S. Mehta Rima M. Saliba Julianne Chen Gabriela Rondon Aimee E. Hammerstrom Amin Alousi Muzaffar Qazilbash Qaiser Bashir Sairah Ahmed Uday Popat Chitra Hosing Issa Khouri Elizabeth J. Shpall Richard E. Champlin Stefan O. Ciurea 《British journal of haematology》2016,173(3):444-455
Post‐transplantation cyclophosphamide (PTCy) is an effective strategy to prevent graft‐versus‐host disease (GVHD) after haploidentical haematopoietic cell transplantation (HCT). We determined the efficacy of PTCy‐based GVHD prophylaxis in human leucocyte antigen (HLA)‐mismatched unrelated donor (MMUD) HCT. We analysed 113 adult patients with high‐risk haematological malignancies who underwent one‐antigen MMUD transplantation between 2009 and 2013. Of these, 41 patients received PTCy, tacrolimus and mycophenolate mofetil (MMF) for GVHD prophylaxis; 72 patients received conventional prophylaxis with anti‐thymocyte globulin, tacrolimus and methotrexate. Graft source was primarily bone marrow (83% PTCy vs. 63% conventional group). Incidence of grade II–IV (37% vs. 36%, P = 0·8) and grade III–IV (17% vs. 12%, P = 0·5) acute GVHD was similar at day 100. However, the incidence of grade II‐IV acute GVHD by day 30 was significantly lower in the PTCy group (0% vs. 15%, P = 0·01). Median time to neutrophil (18 days vs. 12 days, P < 0·001) and platelet (25·5 days vs. 18 days, P = 0·05) engraftment was prolonged in PTCy group. Rates of graft failure, chronic GVHD, 2‐year non‐relapse mortality, relapse, progression‐free survival or overall survival were similar. Our results demonstrate that PTCy, tacrolimus and MMF for GVHD prophylaxis is safe and produced similar results as conventional prophylaxis in patients with one antigen HLA‐MMUD HCT. 相似文献
82.
83.
Performing a preliminary hazard analysis applied to administration of injectable drugs to infants 下载免费PDF全文
84.
Membrane expression of platelet calpain 总被引:1,自引:1,他引:1
Platelet calpain has many platelet substrates, including external membrane proteins. We thus investigated whether platelet calpain II was associated with platelet membranes in unstimulated and thrombin- activated platelets. A monospecific, goat polyclonal antibody was reared to purified platelet calpain II. Sixteen whole platelet lysates were found to contain 4.5 +/- 0.7 micrograms calpain antigen II per 10(8) platelets (mean +/- SEM) as determined by a competitive enzyme- linked immunosorbent assay. Using the dipeptide fluorogenic substrate, Suc-Leu-Tyr-MCA, 17 human platelet lysates contained 3.6 +/- 0.4 micrograms calpain activity per 10(8) platelets. Platelet calpain II was associated with the Triton X-100 insoluble platelet cytoskeletons from both unstimulated and thrombin-activated platelets. When compared with the total cell content of platelet calpain II, calpain antigen (10% to 13%) and calpain activity (24% to 28%) was associated with platelet cytoskeletons in unstimulated and thrombin-activated platelets, respectively. On immunoblot, the heavy chain (80 Kd) of calpain II was detected in platelet cytoskeletons. Subcellular fractionation studies on both unstimulated and thrombin-activated platelets, revealed that half of the total platelet calpain II antigen was associated with cytosol, and the other half was associated with the membrane fraction. Platelet calpain II was not seen on the surface of unstimulated, paraformaldehyde fixed platelets by immunofluorescence. However, on thrombin-activated platelets, rim immunofluorescence was seen, indicating that activated platelets externalize their calpain. This observation was confirmed by the finding that about 2,000 molecules per platelet of an 125I-anti-calpain II Fab' specifically bound to thrombin-activated but not unstimulated platelets. Both dibucaine (1 mmol/L) and platelet activating factor (1.86 mumol/L) in the absence of external Ca++, but not collagen (5 micrograms/mL) or ionophore A23187 (2.5 mumol/L) in the absence of external Ca++, were also able to externalize platelet calpain II antigen, as indicated by a similar level of specific 125I-anti-calpain II Fab'-platelet binding. These combined studies indicate that platelet calpain II is a major protein, comprising 2% of total platelet protein, a substantial portion of which is membrane-associated. When platelets are activated by thrombin and platelet activating factor, calpain II antigen also becomes present on the external platelet surface. 相似文献
85.
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia 总被引:6,自引:0,他引:6 下载免费PDF全文
Garcia-Manero G Kantarjian HM Sanchez-Gonzalez B Yang H Rosner G Verstovsek S Rytting M Wierda WG Ravandi F Koller C Xiao L Faderl S Estrov Z Cortes J O'brien S Estey E Bueso-Ramos C Fiorentino J Jabbour E Issa JP 《Blood》2006,108(10):3271-3279
We conducted a phase 1/2 study of the combination of 5-aza-2'-deoxycytidine (decitabine) and the histone deacetylase inhibitor valproic acid (VPA) in patients with advanced leukemia, including older untreated patients. A group of 54 patients were treated with a fixed dose of decitabine (15 mg/m(2) by IV daily for 10 days) administered concomitantly with escalating doses of VPA orally for 10 days. A 50 mg/kg daily dose of VPA was found to be safe. Twelve (22%) patients had objective response, including 10 (19%) complete remissions (CRs), and 2 (3%) CRs with incomplete platelet recovery (CRp). Among 10 elderly patients with acute myelogenous leukemia or myelodysplastic syndrome, 5 (50%) had a response (4CRs, 1CRp's). Induction mortality was observed in 1 (2%) patient. Major cytogenetic response was documented in 6 of 8 responders. Remission duration was 7.2 months (range, 1.3-12.6+ months). Overall survival was 15.3 months (range, 4.6-20.2+ months) in responders. Transient DNA hypomethylation and global histone H3 and H4 acetylation were induced, and were associated with p15 reactivation. Patients with lower pretreatment levels of p15 methylation had a significantly higher response rate. In summary, this combination of epigenetic therapy in leukemia was safe and active, and was associated with transient reversal of aberrant epigenetic marks. 相似文献
86.
87.
Chan AO Broaddus RR Houlihan PS Issa JP Hamilton SR Rashid A 《The American journal of pathology》2002,160(5):1823-1830
Aberrant crypt foci (ACF) are postulated to be the earliest precursor lesion in colorectal carcinogenesis, and CpG island methylation has been described as an important molecular pathway. We therefore studied methylation in ACF from patients with familial adenomatous polyposis (FAP) or sporadic colorectal cancer. We assessed methylation status of the p16 tumor suppressor gene, MINT1 (methylated in tumor 1), MINT2, MINT31, O(6)-methylguanine-DNA methyltransferase gene, and hMLH1 mismatch repair gene. We compared methylation to ACF histopathology, K-ras proto-oncogene mutation, loss of heterozygosity at chromosome 1p, and microsatellite instability. Methylation was present in 34% (21 of 61) of ACF, including both FAP and sporadic types, but was more frequent in sporadic ACF [53% (18 of 34) versus 11% (3 of 27), P = 0.002], especially dysplastic sporadic ACF [75% (3 of 4) versus 8% (2 of 24), P = 0.004]. MINT31 was more frequently methylated in heteroplastic ACF than dysplastic ACF [35% (11 of 31) versus 7% (2 of 30), P = 0.01]. Strong associations of ACF methylation with K-ras mutation (P = 0.007) and with loss of chromosome 1p (P = 0.04) were observed, but methylation was the only molecular abnormality identified in 16% (10 of 61) of ACF. Our findings suggest that methylation in ACF is an early event in the pathogenesis of a subset of colorectal carcinomas, and that ACF from FAP patients and patients with sporadic colorectal cancer have distinct epigenetic changes that reflect differences in molecular pathogenesis. 相似文献
88.
89.
90.